← Back to Search

Diagnostic Test

Parametric PET/CT for Genitourinary Cancer

N/A

Waitlist Available

Led By Guobao Wang, PhD

Research Sponsored by University of California, Davis

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up one year after treatment

Awards & highlights

Study Summary

This trial is testing a new way to evaluate if kidney cancer treatments are working sooner than the current standard, which could help patients avoid costly and toxic treatments that wouldn't help them.

Who is the study for?

This trial is for adults over 21 with genitourinary cancers, who can consent to treatment and follow the study plan. They must use effective birth control and not be pregnant or in prison. Participants should have a life expectancy of at least 6 months and not have had other investigational drugs within the last month.Check my eligibility

What is being tested?

The study tests a new PET/CT imaging method to quickly evaluate how well cancer treatments are working for metastatic kidney cancer patients, potentially identifying drug efficacy within days to weeks instead of months.See study design

What are the potential side effects?

While this trial focuses on imaging techniques rather than direct treatments, potential side effects may include discomfort from lying still during scans or reactions related to contrast agents used in PET/CT procedures.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ one year after treatment

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~one year after treatment

This trial's timeline: 3 weeks for screening, Varies for treatment, and one year after treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Changes in blood flow

Changes in blood volume

Secondary outcome measures

Correlation with tumor anatomical response

Other outcome measures

Inclusion of Minority Cohort

Trial Design

1Treatment groups

Experimental Treatment

Group I: Patients with GUCExperimental Treatment1 Intervention

Each patient with GUC will first undergo an X-ray CT scan for attenuation correction purpose. After that, 10 mCi 18F-Fludeoxyglucose (18F-FDG) will be injected into the patient through the IV in a period of 10 seconds. The PET scan commences 10 seconds before the FDG injection and lasts for 60 minutes. After the PET scan, the patient gets off the scanner. One blood sample (10cc) will be drawn using a butterfly method with the time recorded.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of California, DavisLead Sponsor

910 Previous Clinical Trials

4,706,980 Total Patients Enrolled

Guobao Wang, PhDPrincipal InvestigatorUniversity of California, Davis

2 Previous Clinical Trials

73 Total Patients Enrolled

Media Library

Parametric PET/CT (Diagnostic Test) Clinical Trial Eligibility Overview. Trial Name: NCT04020978 — N/A

Genitourinary Cancers Research Study Groups: Patients with GUC

Genitourinary Cancers Clinical Trial 2023: Parametric PET/CT Highlights & Side Effects. Trial Name: NCT04020978 — N/A

Parametric PET/CT (Diagnostic Test) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04020978 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the age restriction for this trial inclusive of individuals over thirty?

"This medical research is targeting individuals aged between 21 and 100."

Answered by AI

What is the upper limit of participation in this experiment?

"Affirmative, the research published on clinicaltrials.gov shows that this research project is open to new participants. Dating back to July 16th 2019, and most recently modified on November 21st 2022; 20 individuals are being sought at a single medical centre for participating in the trial."

Answered by AI

Could participants join this experiment at the present time?

"Clinicaltrials.gov shows that the recruitment process for this research is active, with its initial posting being on July 16th 2019 and a recent update occurring in November 21st 2022."

Answered by AI

Who qualifies for participation in this experiment?

"This trial is presently recruiting up to 20 participants who have been diagnosed with genitourinary cancers, aged 21 and 100. Those interested must meet a wide variety of criteria: pathological confirmation of GUC; index metastatic cancer lesion(s) visible through 18F-FDG parametric PET/CT scans; scheduled for targeted therapy such as sunitinib or pazopanib; comprehension of informed consent forms and the study schedule; life expectancy exceeding 6 months; non-reproductive female subjects over 1 year postmenopausal OR those with hysterectomies, bilateral tubal ligations, or ooph"

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Parametric PET of Genitourinary Cancer

2019. "Parametric PET of Genitourinary Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04020978.